Adagio Therapeutics fetches $336m Series C

Adagio Therapeutics Inc, a developer of best-in-class antibodies to broadly neutralize coronaviruses, has closed $336 million in Series C financing.

To read this article, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to read this article and more for free.

Share this